Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
Updated 2026-09-18 · every price checked by hand
How we make money: one company on this page — Coreage Rx — pays us a commission when a reader signs up through our link. It buys them nothing else: not a better score, not a higher place in the table, not the removal of a single criticism. Our scoring method and full disclosure are both public.
If you are on Medicare, this is almost certainly the most useful page on this site. From 1 July 2026, eligible beneficiaries can get certain GLP-1 medications for $50 for a monthly supply.
That is less than every cash-pay programme we track. The cheapest compounded tirzepatide on this site is Trimi at $125 a month and the cheapest semaglutide is Ozari Health at $86. A $50 copay undercuts both, for an FDA-approved product rather than a compounded one.
What was actually announced
CMS will give eligible Medicare beneficiaries access to certain GLP-1 medications for $50 for a monthly supply, beginning 1 July 2026 and running through 31 December 2027.
- It is a time-limited demonstration, not a permanent benefit — it is currently scheduled to end on 31 December 2027.
- You must be enrolled in a Medicare Part D prescription drug plan to be eligible.
- It covers certain GLP-1 medications; CMS has said it will publish more detail for beneficiaries as the programme begins.
- Separately, manufacturers agreed to price the injectable products at around $245 per month for Medicare, with beneficiary copays capped at $50.
- Whether a GLP-1 is appropriate for you is a decision for your doctor — eligibility for the programme is not the same as a clinical recommendation.
Announced in the CMS press release, 6 May 2026. CMS has published further detail at cms.gov, and says it will release more for beneficiaries as the programme starts.
The part people will miss. It is a demonstration with an end date — currently 31 December 2027. It is not a permanent Medicare benefit, and nobody should assume the $50 price continues past that without checking.
What to do about it
- Confirm you are enrolled in a Medicare Part D prescription drug plan — the programme runs through Part D.
- Talk to your doctor about whether a GLP-1 is appropriate for you. Being eligible for a pricing programme is not the same as it being the right treatment.
- If you are currently paying cash for a compounded GLP-1, work out what you would pay under this instead. For most people it will be substantially less.
- Ask specifically which medications are covered. CMS says "certain GLP-1 medications" and the detail matters.
- If you are about to prepay a year with a cash-pay provider, check the refund terms first. A twelve-month prepayment signed in June could look expensive in July.
How it compares with paying cash
| Route | Monthly | FDA-approved? |
|---|---|---|
| Medicare GLP-1 Bridge (from 1 July 2026) | $50 | Yes |
| Cheapest compounded semaglutide (Ozari Health) | $86 | No — compounded |
| Cheapest compounded tirzepatide (Trimi) | $125 | No — compounded |
| Wegovy pill, self-pay | $149+ | Yes |
| Foundayo (orforglipron), self-pay | $149+ | Yes |
Separately, manufacturers agreed to price the injectable products at around $245 a month for Medicare, with beneficiary copays capped at $50. The two things together mean the cash-pay compounded market is no longer the obvious cheap option it was in 2024.
If you are not on Medicare
This programme will not help you, but the approved oral products might — both now start at $149 a month. We go through them in the FDA-approved pills. If you are still paying cash for a compounded injection, compare it against those before renewing.
Nothing here is medical advice, and we are not affiliated with CMS or Medicare. Check your own eligibility with Medicare directly and your treatment with your doctor.